Gabelli Commercial Aerospace and Defense ETF (ARCA: GCAD)

Dernières nouvelles pour Gabelli Commercial Aerospace and Defense ETF (ARCA:GCAD)

Industrials

Financial Services

Technology

Consumer Defensive

Healthcare

Real Estate

Consumer Cyclical

Basic Materials

The Fund will seek to achieve its investment objective by investing, under normal market conditions, at least 80 percent of its net assets in income producing equity securities including securities in the aerospace and defense sectors. Aerospace companies include manufacturers, assemblers and distributors of aircraft and aircraft parts. Defense companies include producers of components and equipment for the defense industry, such as military aircraft, radar equipment and weapons. The Fund defines an aerospace and defense company as a company that derives at least 50 percent of its revenues from, or devotes 50 percent of its assets to, aerospace or defense related activities, or has an identified business line that derives at least 50 percent of its revenues from, or devotes 50 percent of its assets to, aerospace and/or defense related activities. Income producing equity securities include U.S. exchange-listed common stock and preferred stock. The Fund may also invest in foreign securities by investing in American Depositary Receipts.

Spirit Aerosystems

Boeing Co.

Moog Inc

Ducommun Inc*

Honeywell International Inc.

Lockheed Martin Corp

Textron

Curtiss Wright Corp (cw)

Rtx Corp.

Northrop Grumman Corp.

Mercury Systems Inc

Hexcel Corp

Howmet Aerospace Inc.

Moog Inc.

Stride Inc

Firstcash Inc

Radnet Inc

Bjs Wholesale Club Holdings

Korn Ferry

Stonex Group Inc

Merit Medical Systems Inc

ollie's Bargain Outlet

Slm Corp

Gabelli Commercial Aerospace and Defense Fund

Throughout the last three months, 7 analysts have evaluated Chemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CC#NYSE">CC</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.71, along with a high estimate of $22.00 and a low estimate of $13.00. A decline of 18.56% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1751576451_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Chemours. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Chemours. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Chemours compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Chemours's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Chemours's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Chemours analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Chemours: A Closer Look</h2>
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal &amp; Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
<h3>A Deep Dive into Chemours's Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3M period, Chemours showcased positive performance, achieving a revenue growth rate of 0.44% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Chemours's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.29% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Chemours's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.68%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Chemours's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.05%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Chemours's debt-to-equity ratio stands notably higher than the industry average, reaching 7.57. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Expectations For Chemours's Future

Simon Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) has outperformed the market over the past 5 years by 5.6% on an annualized basis producing an average annual return of 20.39%. Currently, Simon Property Group has a market capitalization of $54.40 billion. 
Buying $1000 In SPG: If an investor had bought $1000 of SPG stock 5 years ago, it would be worth $2,418.98 today based on a price of $166.74 for SPG at the time of writing.
<h3>Simon Property Group's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751576425_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Simon Property Group 5 Years Ago Would Be Worth This Much Today

In the current session, the stock is trading at $57.95, after a 1.12% increase. Over the past month, Fidelity National Finl Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) stock increased by 7.37%, and in the past year, by 20.56%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1751576417_0.png" alt="Past Year Chart" />

<h3>A Look at Fidelity National Finl P/E Relative to Its Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 23.37 in the Insurance industry, Fidelity National Finl Inc. has a lower P/E ratio of 14.22. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1751576417_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into Fidelity National Finl Inc's Price Over Earnings

LRHC

Trading Halt: Halted at 4:50:00 p.m. ET - Trading Halt: Halt News Pending

LVLU

FLYE

Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) has outperformed the market over the past 20 years by 6.94% on an annualized basis producing an average annual return of 15.44%. Currently, Equinix has a market capitalization of $76.60 billion. 
Buying $1000 In EQIX: If an investor had bought $1000 of EQIX stock 20 years ago, it would be worth $17,641.78 today based on a price of $787.00 for EQIX at the time of writing.
<h3>Equinix's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751575513_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EQIX

Here's How Much $1000 Invested In Equinix 20 Years Ago Would Be Worth Today

On June 30, 2025, the Board of Directors of Sharps Technology, Inc. (the "Company") appointed Paul Danner to serve as the Company's Executive Chairman, replacing Soren Christiansen, who was a non-executive Chairman.
&nbsp;
In connection with Mr. Danner's appointment and resulting change in independence status, the Board appointed Timothy Ruemler to serve as Chairman of the Audit Committee. Additionally, the Board appointed Soren Christiansen to fill Mr. Danner's seat on the Compensation Committee.

Management

STSS

Sharps Technology Appoints Paul Danner As Executive Chairman

On July 1, 2025, Beam Therapeutics Inc. (the "Company") entered into an Agreement and Plan of Merger pursuant to which it acquired an early-stage life sciences company (the "Agreement"). As consideration for the acquisition, the Company agreed to issue to the shareholders of the company (i) 403,128 shares of the Company's common stock, par value $0.01 per share (the "Common Stock") as an upfront payment (the "Upfront Shares") and (ii) up to an aggregate of $89,000,000 in potential additional payments upon the achievement of certain development, clinical and commercial milestones, which milestone payments may be made in cash or in shares of Common Stock (the "Milestone Shares") in the Company's sole discretion. Based on the closing price of the Common Stock of $17.01 per share on June 30, 2025, the maximum number of Milestone Shares issuable pursuant to the Agreement is 5,232,216 shares; however, the exact number of Milestone Shares cannot be determined at this time, and the Company intends to file an amendment to this Form 8-K to disclose the exact number of Milestone Shares issued, if any. The issuance of the Upfront Shares and any Milestone Shares that the Company elects to issue in satisfaction of milestone payments will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws. Based in part upon the representations of the shareholders of the company in the Agreement, the Company has relied on the exemption from the registration requirements of the Securities Act under Section 4(a)(2) thereof for a transaction by an issuer not involving any public offering.&nbsp;

BEAM

Beam Therapeutics Enters Agreement To Acquire Early-Stage Life Sciences Company For 403,128 Upfront Shares And Up To $89M In Milestone Payments

Preliminary Q2 2025 Operating Results
Emeren is also providing its preliminary financial updates for the second quarter of 2025. Based on currently available information, the Company expects the following:
<ul>
<li>A non-cash impairment of no less than $20 million on global property, plant, and equipment (PPE), primarily reflecting an updated fair value assessment of certain power station assets in accordance with U.S. GAAP.</li>
</ul>

Guidance

Emeren Expects A Non-Cash Impairment Of No Less Than $20M On Global Property, Plant, And Equipment

Investor Kevin O&#8217;Leary, who just finished taping &#8220;a big chunk&#8221; of Season 17 of &#8220;Shark Tank,&#8221; says it&#8217;s shaping up to be one of the most exciting yet.&nbsp;
It&#8217;s also the first without longtime shark Mark Cuban, who has <a href="https://www.benzinga.com/general/entertainment/25/05/45472538/mark-cuban-bids-farewell-to-shark-tank-how-to-watch-finale-and-whats-next-for-hit-show">announced</a> he would be leaving the show after Season 16. His absence marks a major shift, but the energy on set remains high, according to O&#8217;Leary.
<h2 class="wp-block-heading">Big Companies, Bigger Problems</h2>
&#8220;The market for venture capital has dried up,&#8221; O&#8217;Leary said in a recent <a href="https://x.com/kevinolearytv/status/1938382234798715257">post on X</a>. &#8220;It reminds me of 2008, 2009.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. <a href="https://www.benzinga.com/money/this-company-may-have-found-a-way-to-treat-cancer-by-tricking-the-bodys-immune-system-and-early-studies-show-some-promise-find-out-how-you-can-invest-in-the-future-of-cancer-treatment">Back a bold new approach to cancer treatment with high-growth potential.</a></li>
<li>Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — <a href="https://www.benzinga.com/money/americans-spend-1000-per-year-on-plastic-water-bottles-kara-pod-gives-you-clean-drinking-water-by-pulling-moisture-from-the-air">And You Can Invest At Just $6.37/Share</a></li>
</ul>
According to O&#8217;Leary, even large companies with solid sales are now turning to &#8220;Shark Tank&#8221; to <a href="https://www.benzinga.com/personal-finance/25/06/46034399/startup-investing-used-to-be-for-millionaires-not-anymore">raise money</a> and get global exposure. &#8220;They just can&#8217;t raise money and so they&#8217;re coming to the &#8216;Shark Tank&#8217; for two things: to get that global exposure, it&#8217;s in 154 countries, and of course to seek capital,&#8221; he said.
O&#8217;Leary added that the show has been attracting a wider range of businesses, including those already generating serious revenue. &#8220;Every year seems to be the same. The deals get bigger and the companies get larger.&#8221;
He said this season is packed with innovation, including healthy food alternatives, tech, and even artificial intelligence. &#8220;I keep saying this every year: this is the best year ever,&#8221; he said. &#8220;The number of innovation, companies, like just huge. Really interesting.&#8221;
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wiseradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. </a>&nbsp;
<h2 class="wp-block-heading">His Advice for Entrepreneurs? Just Start</h2>
In another recent <a href="https://x.com/kevinolearytv/status/1938345869071298659">post</a>, O&#8217;Leary addressed the uncertainty of today's economy, especially with crypto booming, interest rates fluctuating, and geopolitical risks piling up. His advice to new entrepreneurs is simple: just start.
&#8220;More than half the time [successful companies are founded] in times of extreme stress or volatility,&#8221; he said. &#8220;It really doesn&#8217;t have a good or bad time to start — it&#8217;s just start is what you have to do.&#8221;
He also pointed out that failure is a constant part of entrepreneurship. &#8220;The <a href="https://www.benzinga.com/news/topics/25/06/45772125/90-of-startups-fail-heres-whats-going-wrong">majority of the startups fail</a> anyways, and they always have since the 1950s when they&#8217;ve been tracking venture capital,&#8221; he noted.
See Also: Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — <a href="https://www.benzinga.com/money/meet-the-company-seeking-to-give-americans-energy-independence-and-learn-how-you-can-become-an-early-investor">Now Raising at $3/Share</a>
Still, he said, the journey often pays off. &#8220;The nature of the journey is exactly that — it&#8217;s never a destination. It&#8217;s a journey,&#8221; O&#8217;Leary said.
For many entrepreneurs, he added, the payoff comes later in the form of a buyout, going public, or getting acquired. &#8220;And then they just get back on the road and continue the journey.&#8221;
Read Next: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Image: Shutterstock

Kevin O'Leary Says The Venture Capital Market Has 'Dried Up' Like In 2008. Now Even Big Companies Are Coming On 'Shark Tank' For Funding

Quantum computing stocks had a big week with a completed offering and bullish analyst coverage<a href="https://www.benzinga.com/trading-ideas/movers/25/07/46193784/d-wave-quantum-stock-is-trading-higher-tuesday-whats-happening"> of several stocks.&nbsp;</a>
Here&#8217;s a look at the highlights, lowlights and news catalysts in the quantum computing sector.
<h3 class="wp-block-heading">D-Wave Quantum &#8211; QBTS&nbsp;</h3>
D-Wave Quantum, Inc. (NYSE: QBTS) announced on Tuesday that <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46193784/d-wave-quantum-stock-is-trading-higher-tuesday-whats-happening" target="_blank" rel="noopener">it had </a><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46193784/d-wave-quantum-stock-is-trading-higher-tuesday-whats-happening">successfully </a>sold $400 million of its common stock, completing the offering at an average price of $15.18 per share.
On Wednesday, Cantor Fitzgerald analyst Troy Jensen <a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46232263/d-wave-surges-1326-whats-driving-quantum-computings-newest-star">initiated coverage</a> on D-Wave Quantum with an Overweight rating and a $20 price target. 
Read Next:<a href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/07/46245952/metas-growth-sizzles-but-wait-for-a-pullback-before-buying-in?utm_source=articleShare"> Meta&#8217;s Growth Sizzles, But Wait For A Pullback Before Buying In</a>
Jensen said the company is in the very early innings of commercializing its technology and is positioned to capture 15% of the quantum hardware, software and services market by 2035.&nbsp;&nbsp;
D-Wave Quantum stock has gained 16% over the past five days.&nbsp;&nbsp;
<h3 class="wp-block-heading">Rigetti Computing &#8211; RGTI&nbsp;</h3>
Cantor&#8217;s Jensen also<a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46230597/quantum-computings-dark-horse-rigetti-stands-at-the-edge-of-greatness"> initiated coverage</a> on Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) with an Overweight rating and a bullish $15 price target.
The analyst noted that after challenging years in 2022 and 2023, Rigetti's share price has rallied since late 2024, increasing by approximately 1,008% over the last 52 weeks.
He also applauded Rigetti's partnership with Quanta Computer and sees the collaboration helping to accelerate the development and commercialization of superconducting quantum computing.&nbsp;
<h3 class="wp-block-heading">IonQ&nbsp;&#8211; IONQ</h3>
IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares rallied about 11% this week. The stock also received a Buy rating<a href="https://www.benzinga.com/analyst-stock-ratings/initiation/25/07/46229237/cash-rich-ionq-to-capture-20-of-quantum-market-by-2035-analyst"> from Cantor</a> and a $45 price forecast. 
Jensen pointed to IonQ's strong financial position, noting that the company ended the first quarter of 2025 with nearly $700 million in cash following a $373 million equity raise.
<h3 class="wp-block-heading">Quantum Computing &#8211; QUBT</h3>
QUBT: The Cantor analyst initiated coverage on Quantum Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) with a Neutral rating and a $15 price target, well below the stock's current $20 levels. However, the stock remained strong with gains of 67.5% over the past month and over 4,600% in the past year. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46236537/openai-says-tokens-are-not-equity-no-partnership-with-robinhood-musk-says-ai-companys-equity-is-fake?utm_source=articleShare">OpenAI Says Tokens Are Not Equity, No Partnership With Robinhood: Musk Says AI Company&#8217;s Equity &#8216;Is Fake&#8217;</a></li>
</ul>
Image: Shutterstock

Initiation

Movers

Tech

IONQ

QBTS

QUBT

RGTI

Quantum Stock Watch: Bullish Analyst Coverage On IonQ, D-Wave, Rigetti Computing

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) has outperformed the market over the past 10 years by 7.87% on an annualized basis producing an average annual return of 19.69%. Currently, Autodesk has a market capitalization of $67.39 billion. 
Buying $1000 In ADSK: If an investor had bought $1000 of ADSK stock 10 years ago, it would be worth $5,942.20 today based on a price of $315.00 for ADSK at the time of writing.
<h3>Autodesk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751574617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADSK

Here's How Much $1000 Invested In Autodesk 10 Years Ago Would Be Worth Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 60.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed up 22.01% at $0.25</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 16.32% at $1.04</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 14.50% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 8.70% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 8.18% at $0.54</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Growth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 7.62% at $1.28</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 7.10% at $0.29</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 5.31% at $0.31</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 3.58% at $0.05</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 25.00% at $0.0009</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 13.04% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 10.00% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 8.29% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 7.12% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 6.40% at $0.54</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 6.40% at $0.86</li>
<li><a href="https://www.benzinga.com/quote/RIV">Rivernorth Opps Fund</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#NYSE">RIV</a>) shares closed down 4.46% at $12.35</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

BBRRF

BLGVF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CNTMF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

FFNTF

ITHUF

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

NWVCF

OILFF

TLRY

UGRO

YCBD

ZDPY

Bullish Sentiment Across The Cannabis Space - Check Full Movers For July 3, 2025

As previously disclosed, on June 10, 2025, Jean-Marc Bellemin notified Iovance Biotherapeutics, Inc. (the "Company") that he would be resigning as Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer of the Company to pursue other opportunities, effective July 10, 2025. On June 30, 2025, the Company and Mr. Bellemin mutually agreed that Mr. Bellemin would separate from the Company, effective June 30, 2025.
&nbsp;
Effective as of June 30, 2025, Matthew W. Rosinack, the Company's Senior Vice President, Finance, was appointed as the Company's interim Principal Financial Officer and Principal Accounting Officer.

IOVA

Iovance Biotherapeutics CFO Jean-Marc Bellemin Departs Early; Matthew Rosinack Appointed Interim CFO And Principal Accounting Officer

Antero Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AR#NYSE">AR</a>) has outperformed the market over the past 5 years by 50.28% on an annualized basis producing an average annual return of 65.07%. Currently, Antero Resources has a market capitalization of $11.70 billion. 
Buying $1000 In AR: If an investor had bought $1000 of AR stock 5 years ago, it would be worth $12,587.84 today based on a price of $37.62 for AR at the time of writing.
<h3>Antero Resources's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751573712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Antero Resources Stock In The Last 5 Years

On July 3, 2025, Lantern Pharma Inc., a Delaware corporation (the "Company"), entered into an ATM Sales Agreement (the "Sales Agreement") with ThinkEquity LLC (the "Agent"), pursuant to which the Company may offer and sell up to $15,530,000 maximum aggregate offering price of shares (the "Placement Shares") of common stock, par value $0.0001 per share, of the Company ("Common Stock") from time to time through the Agent, acting as sales agent or principal, in such amounts as the Company may specify by notice to the Agent, in accordance with the terms and conditions set forth in the Sales Agreement.

Offerings

LTRN

Lantern Pharma Enters $15.53M At-The-Market Offering Agreement With ThinkEquity

SHIM

Shimmick Files For Stock Shelf Of Up To $20M

ASST

Asset Entities Enters Amended Merger Agreement On June 27, 2025; Strive Stockholders To Receive Merger Consideration; Merger End Date Extended To February 6, 2026

MingZhu Logistics Holdings Limited ("MingZhu" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>), an elite provider of logistics and transportation services to businesses, today announced it has entered into a Share Purchase Agreement (the "SPA") to acquire 100% equity of Shenzhen Mingzhuchun Wine Co., Ltd. ("Mingzhuchun"), which operates its liquor distribution business through its two subsidiaries Xiamen Bainian Qianzhuang Wine Group Co., Ltd. and Ningde Mingfu Wine Co., Ltd. in China.
Under the SPA, MingZhu shall acquire 100% of Mingzhuchun in exchange for the issuance of 2,000,000 ordinary shares of Mingzhu upon closing. The shareholder of Mingzhuchun shall receive additional First Earnout Payment of 2,000,000 ordinary shares and Second Earnout Payment of 2,000,000 ordinary shares respectively if the net income of Mingzhuchun is no lower than US$1 million for the fiscal year 2025 and 2026 respectively.
The closing of the transaction contemplated by the SPA is subject to the satisfaction of the closing conditions set forth therein.

YGMZ

MingZhu Logistics To Acquire Mingzhuchun Wine Co. In Exchange For The Issuance Of 2M Ordinary Shares Of Mingzhu Upon Closing; Additional First Earnout Payment Of 2M Ordinary Shares And Second Earnout Payment Of 2M Ordinary Shares Respectively If The Net Income Of Mingzhuchun Is No Lower Than $1M For The Fiscal Year 2025 And 2026 Respectively

Earnings

Press Releases

GAMCO Investors, Inc. Reports Results for the 2nd Quarter 2024

GAMCO Investors, Inc. Reports Results for the Fourth Quarter and Year Ended December 31, 2024

Comments

Gabelli Commercial Aerospace and Defense ETF

Actualités

Dernières nouvelles pour Gabelli Commercial Aerospace and Defense ETF (ARCA:GCAD)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL